Advertisement

Ceftazidime Injection

[21 November 2016]

Products Affected - Description

Fortaz injection, Teligent
1 gram/50 mL, premixed bag, 24 count (NDC 24987-0412-00)
2 gram/50 mL, premixed bag, 24 count (NDC 24987-0413-00)
 
Fortaz powder for solution for injection, Teligent
1 gram, vial, 10 count (NDC 24987-0378-10)
6 gram, vial, 6 count (NDC 24987-0382-37)
 
Tazicef powder for solution for injection, Hospira
1 gram, ADD-Vantage vial, 25 count (NDC 00409-5092-16)
2 gram, ADD-Vantage vial, 10 count (NDC 00409-5093-11)
2 gram, vial, 10 count (NDC 00409-5084-11)
6 gram, vial, 6 count (NDC 00409-5086-11)
 
Ceftazidime powder for solution for injection, Sagent
1 gram, vial, 25 count (NDC 25021-0127-20)
2 gram, vial, 10 count (NDC 25021-0128-50)
6 gram, vial, 6 count (NDC 25021-0129-99)
 
Ceftazidime powder for solution for injection, WG Critical Care
2 gram, vial, 10 count (NDC 44567-0236-10)

Reason for the Shortage

  • IGI Laboratories changed its name to Teligent in late-October 2015.
  • Covis divested Fortaz injection to IGI Laboratories in October 2015.
  • Hospira had Tazicef on shortage due to manufacturing delays.
  • Sagent has ceftazidime injection on shortage due to manufacturing delays.
  • Sandoz discontinued ceftazidime 1 gram and 2 gram vials in 2015.

Available Products

Fortaz powder for solution for injection, Teligent
1 gram, TwistVials 25 count (NDC 24987-0434-00)
2 gram, vial, 10 count (NDC 24987-0379-34)
2 gram, TwistVials 10 count (NDC 24987-0435-00)
500 mg, vial, 10 count (NDC 24987-0377-10)
 
Tazicef powder for solution for injection, Hospira
1 gram, vial, 25 count (NDC 00409-5082-16)
 
Ceftazidime injection, BBraun
1 gram/50 mL, premixed bag, 24 count (NDC 00264-3143-11)
2 gram/50 mL, premixed bag, 24 count (NDC 00264-3145-11)
 
Ceftazidime powder for solution for injection, WG Critical Care
1 gram, vial, 25 count (NDC 44567-0235-25)
6 gram, vial, 6 count (NDC 44567-0237-06)

Estimated Resupply Dates

  • Teligent has Fortaz 1 gram and 6 gram vials on back order and the company estimates a release date of early-December 2016. The 1 gram/50 mL and 2 gram/50 mL premixed bags are on back order and the company estimates a release date of early-December 2016.
  • Sagent has ceftazidime 1 gram, 2 gram, and 6 gram vials on back order and the company estimates a release date of November 2016.
  • Hospira has Tazicef 1 gram ADD-Vantage vials on back order and the company estimates a release date in early-December 2016. Tazicef 2 gram ADD-Vantage vials are on back order and the company estimates a release date of late-November 2016. Tazicef 2 gram vials are on back order and the company estimates a release date of early-February 2017. Tazicef 6 gram vials are on back order and the company estimates a release date of mid-January 2017.
  • WG Critical Care has ceftazidime 2 gram vials on back order and the company estimates a release date of February 2017.

Related Shortages

Updated

November 21, 9 and 7, October 12 and 4, September 7, August 25, 3 and 2, June 24, May 27 and 20, April 6, March 21, February 25, January 28, 14 and 6, 2016; December 3, November 5, October 23, September 23, August 12, July 21, June 11, May 21, April 27, March 3, February 20, January 23, 2015; December 22, November 21, October 3, September 5, August 15, July 17, June 24, April 24, March 3, February 24, January 6, 2014; December 20, November 13, October 14, August 30, July 18, June 13, May 20, April 24, March 8, February 13, January 28, 2013; December 24 and 10, November 30, October 22, September 27, August 9, July 25, June 12, April 24, March 30, February 8, January 10, 2012; December 21, November 29, 2011, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing